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Glucagon-like peptide 1 (GLP-1) is a small peptide component of the prohormone, proglucagon, that is produced in the gut.
Exendin-4, a GLP-1 receptor agonist originally isolated from the saliva of H. suspectum or Gila monster, is a peptide that
shares sequence and functional homology with GLP-1. Both peptides have been demonstrated to stimulate insulin secretion,
inhibit glucagon secretion, promote satiety and slow gastric emptying. As such, GLP-1 and Exendin-4 have become attractive
pharmaceutical targets as an adjunctive therapy for individuals with type II diabetes mellitus, with several products currently
availableclinically.Herein wesummarizethecell biologyleadingtoGLP-1production andsecretion fromintestinalL-cells andthe
endocrine functionsofthispeptide andExendin-4 inhumans.Additionally, gene therapeutic applicationsofGLP-1andExendin-4
are discussed with a focus on recent work using the salivary gland as a gene therapy target organ for the treatment of diabetes
mellitus.
1.Introduction
A great deal of research has been performed on glucagon-
like peptide-1 (GLP-1) since the initial characterization of
glucagon-like substances secreted from the intestine in re-
sponse to oral glucose [1]. A search of the literature
identiﬁes many articles describing original data as well as
many excellent reviews (Holst [2], Riedel and Kieﬀer [3],
and Brubaker [4]). Therefore, it is not the intent of this
review to repeat what has previously been written, but to
summarize what is known about GLP-1 with a focus on gene
therapy using expression vectorsof GLP-1 and otherincretin
mimetics in the salivary gland for the treatment of type 2
diabetes mellitus (T2DM).
2.CellBiology
Glucagon-like peptide-1 (GLP-1(7–37)) is a 30 amino acid
peptide that is initially synthesized as part of proglucagon,
a prohormone composed of 180 amino acids (NCBI ref-
erence for human proglucagon, NP 002045.1). Within the
proglucagonpeptide lie the sequencesof severalsmaller pep-
tide hormones, such as glucagon, GLP-1, GLP-2, glicentin,
and oxyntomodulin. Proglucagon is expressed in pancre-
atic α-cells within the Islets of Langerhans and also in
intestinal endocrine L cells [5, 6]. In these specialized cells,
proglucagon is intracellularly traﬃcked to the regulated
secretory pathway where it can be processed into the smaller
peptide hormone productsindicated above. However, due to
diﬀerential expression of the prohormone convertases (PCs)
in each ofthese tissues[7–10],proglucagonisprocessed such
that glucagon is produced in the pancreas by PC2 [11, 12]
and GLP-1 is produced in the gut by PC1 [13–15]. The GLP-
1 peptide can then undergo additional processing at both
termini. Atthe amino terminus, six amino acids are removed
to generate a new, mature N-terminus that is involved in
activating the GLP-1 receptor in target tissues [16, 17]. The
carboxyl terminus is trimmed by carboxypeptidase E [18]
to remove two arginine residues, allowing a newly exposed2 Experimental Diabetes Research
glycine residue to be amidated by the enzyme, peptidyl alpha
amidating mono-oxygenase [19]. GLP-1 is stored within
secretory ranules of L cells until it is released in a stimulus
dependent manner. GLP-1 is secreted into the bloodstream
in response to taste receptor activation [20] and nutrients
present in the digestive tract after a meal [21, 22] including
glucose, amino acids, and, as recently demonstrated, some
selected tetrapeptides [23]. In addition, neuroendocrine
input [24] involving signaling by leptin, insulin, and gastric
inhibitory peptide as well as muscarinic receptor activation
[25] are involved in stimulated GLP-1 secretion from L cells.
3.Endocrinology
Following secretion of GLP-1 in vivo, it is estimated that
approximately 30% of circulating GLP-1 survives long
enough to reach the pancreas [26]. GLP-1 has a biological
half-life of 2-3min, similar to that of insulin, and is rapidly
degraded by dipeptidyl aminopeptidase IV (DPP IV). Upon
reaching thepancreas, GLP-1 inducesthesecretion ofinsulin
from β-cells in a glucose-dependent manner as well as
inhibits glucagon secretion from α-cells. Importantly, it has
also been shown that GLP-1 enhances β-cell proliferation
with a subsequent increase in β-cell mass (reviewed in
[27]). This results in an increase in insulin availability under
conditions of high demand and recovery of β-cell mass
previously lost by a progressive reduction of pancreatic
β-cell mass and function as a consequence of T2 DM.
Additionally, GLP-1 restores glucose sensitivity to β-cells
[28] and potentiates insulin-stimulated glucose utilization in
pancreatized dogs [29]. GLP-1 also functions to slow gastric
emptying[30],allowing amore controlledeﬄuxofnutrients
into the intestine and to the circulation. The controlled
releaseofnutrientstothecirculationinturnresultsinamore
controlled nutrient uptake response by the tissues in the
body. Additionally, a central role of GLP-1 in the regulation
of satiety has been shown [31].
4.Exendin-4
Exendin-4 is a 39 amino acid peptide that shares similar
functional properties with GLP-1 and was identiﬁed in
the venom of the lizard, Heloderma suspectum, commonly
k n o w na st h eG i l am o n s t e r( r e v i e w e di n[ 32]). While
not a GLP-1 ortholog, exendin-4 shares 53% amino acid
homology with full-length GLP-1. Due to a glycine residue
in position 8, it is more resistant to degradation by DPP IV
and hence has a longer biological half-life (∼3-4h) in the
circulatory system [33]. As mentioned, exendin-4 acts as a
GLP-1 receptor agonist and was shown to increase cAMP
in guinea pig pancreas [34] and stimulate insulin secretion
not only from mouse insulinoma cell lines but also rat
Islet isolates [35]. Similar to that of GLP-1 in humans and
mammals, exendin-4 has been shown to inhibit glucagon
secretion, stimulate insulin secretion, protect against β-cell
apoptosis, promote β-cell proliferation, promote satiety, and
inhibit gastric emptying [32].
5.Gene Delivery ofGLP-1
and Exendin-4Constructs
The ability of GLP-1 and its analogues to stimulate insulin
secretion in a glucose-dependent manner makes these
moleculesattractivepotentialtherapiesforT2DM.However,
the short half-life of GLP-1 in serum would necessitate
repeated dosing, making injection with a recombinant
peptidean expensiveandinconvenienttreatment strategy.To
circumvent these shortcomings, many groups have explored
alternative methods for expression and delivery of modiﬁed
GLP-1 peptides and analogues including cell engineering
[3, 36] and, more commonly, gene therapeutic approaches.
Several groups have demonstrated expression and secre-
tion of GLP-1 following delivery of viral or plasmid gene
therapy vectors either via intravenous (IV) injection [37–
42] or intraperitoneal injection [43, 44]. As a whole, these
studies illustrate that in vivo expression of a transgenic GLP-
1p e p t i d eh a dp o s i t i v ee ﬀects on glucose homeostasis and
could delay the onset of diabetes in both T1 and T2 DM
models. Additionally, Samson and colleagues demonstrated
that IV injection of a helper-dependent adenovirus encoding
exendin-4 was able to improve glucose homeostasis in a T2
DM model [45]. While eﬀective in animal models, the
inherent risks involved in systemic administration of gene
therapy vectors make targeted delivery of vectors an appeal-
ing alternative for treatment of patients.
Several studies from the laboratory of Dr. Q. Wang have
used “plasmid-based, electroporation-enhanced intramus-
cular gene therapy” to target delivery of vectors encoding
GLP-1 or exendin-4 fusion proteins into mouse models of
DM [46–48]. In initial studies, an active GLP-1 peptide
or an exendin-4 peptide was fused to the heavy chain
constant regions (Fc regions) of mouse IgG to generate
bivalent peptides that have putative increased half-life and
potency in vivo. Plasmids encoding these constructs were
directly injected into the muscle of mice with T1 DM (strep-
tozotocin-induced) or T2 DM (db/db mice) and circulating
fusion peptides were detected in plasma for at least 3-4
weeks following injection. The GLP-1 fusion peptide was
shown to improve glucose tolerance in both models of DM
[46, 47] and the exendin-4 fusion peptide was also shown
to improve glucose homeostasis and ameliorate T1 DM
symptoms when tested in mice treated with chronic low
doses of streptozotocin [46].
The studies of the GLP-1 fusion peptide were taken
a step further in 2010 when Liu and colleagues directed
site-speciﬁc integration of the GLP-1/Fc fusion peptide
plasmid DNA into the genome of transgenic mice carrying
the human adeno-associated virus S1-(AAVS1-) integrating
region [48]. Peak levelsof circulating bivalent GLP-1 peptide
were achieved 2 weeks following intramuscular injection
and subsequent integration of the plasmid construct into
genomic DNA, with sustained plasma levels through 10
weeks of analysis. When tested in high-fat-diet-challenged
mice,thoseexpressing theGLP-1 fusionpeptidefrommuscle
had decreased weight gain and food intake over time,
retained normal levels of circulating leptin and ghrelin, and
demonstrated an improved insulin response in an insulinExperimental Diabetes Research 3
tolerance test. When taken together, these studies demon-
strate the potential of targeted gene therapy for treatment of
diabetes and other endocrine deﬁciencies.
6.The SalivaryGland asaGene TherapyTarget
Organforthe Treatmentof T2DM
The salivary gland (SG) has been demonstrated to be an
eﬀective target organ for gene therapy vectors in several
animal models, and a Phase I/II clinical trial evaluating the
safety and eﬃcacy of recombinant adenoviral vector delivery
to the parotid SG is currently ongoing [49]. Salivary glands
possess many characteristics that make them suitable for
gene transfer (reviewed in [50]). Perhaps foremost of these
characteristics is that unlike liver or lung, SGs are not critical
forlifeorgans, and intheeventofan adversereaction asingle




Salivary glands can produce and secrete large quantities
of protein, an attribute making SGs highly suitable for gene
therapy to treat single protein deﬁciency disorders. In addi-
tion to treating inducible models of endocrine disorders, it
has recently been demonstrated that gene therapeutic vector
deliverytoSGscanbeusedtotreatinborngeneticerrorssuch
as Fabry disease which exhibits a deﬁciency in the lysosomal
enzyme alpha-galactosidase A [51]. Although SG epithelial
cells are primarily exocrine, it is hypothesized that the
SG constitutive secretory pathway (CSP) conveys transgenic
proteins to the circulation via the basolateral membrane
(reviewed in [49]). This has been supported by animal
studies from our group demonstrating that therapeutically
relevant levelsofgrowthhormone and parathyroid hormone
were present in serum following SG transduction, indicating
thepotentialforSGgenetherapytotreatendocrinedisorders
[52, 53].
As a proof-of-principle for SG-mediated treatment of
diabetes, we have recently shown that transduction of mouse
SGs with a recombinant adenovirus encoding a GLP-1
peptide is able to delay the onset of T1 DM in mice [54].
The adenovirus used in these studies (Ad-GLP-1) contains
a modiﬁed human GLP-1 cDNA sequence encoding the
activeGLP-1(7–37)peptidewithanAlatoGlysubstitutionat
position eight to confer resistance to DPP-IV. This construct
was demonstrated to produce a bioactive GLP-1 peptide
that was resistant to DPP-IV degradation and was able to
stimulate insulin secretion from pancreatic β-cells in vitro.
Ad-GLP-1 was then delivered to the submandibular
glands of intact mice by retroductal instillation [55] to deter-
mine the route of GLP-1 peptide secretion and the capacity
for bioactivity in vivo. GLP-1 expressed by the SGs was
detected in the serum of these mice and was able to rapidly
reduce serum glucose levels in a glucose tolerance test when
compared to animals treated with a control (Luciferase-
containing, Ad-Luc) adenovirus. Furthermore, in keeping
with the glucose-dependentmechanism of GLP-1 action, the
blood glucose levelsof fasted animals treated with Ad-GLP-1
were indistinguishable from those treated with Ad-Luc.
After establishing that bioactive transgenic GLP-1 was
secreted tothecirculation,we testedtheabilityofSG-derived
GLP-1 to ameliorate diabetes in an inducible model. In
these studies, Ad-GLP-1 or Ad-Luc was delivered to SGs,
one day later, all mice were then treated with the beta-
cell-speciﬁc toxin alloxan, and blood glucose values of Ad-
GLP-1- or Ad-Luc-treated mice were followed throughout




after alloxan treatment. We are currently generating adeno-
associated viral (AAV) vectors capable of stable, long-term
GLP-1 and exendin-4 expression in order to test the eﬃcacy
of SG-derived GLP-1 and its agonist in treating genetic
models of T2 DM and obesity. Preliminary data strongly
suggest that long-term expression may be achieved.
Thus, the use of the SG as a tissue to express GLP-1
or exendin-4 by adeno- or adeno-associated viral vectors,
demonstrate a means to accomplish a noninvasive delivery
of gene therapy vectors for the treatment of DM.
7.Conclusion
The biology of GLP-1 and its potential use in gene therapy
for the treatment of T2 DM is evident from the cache of
papers available on the topic. GLP-1 appears to have all the
requisitepropertiestomaintain homeostaticlevelsofglucose
inordertoeﬀectivelytreatT2DM.Indeed,DPPIVinhibitors
(e.g., Sitagliptin), which prolong the half-life of a patient’s
endogenous GLP-1, and synthetic GLP-1 receptor agonists
(e.g., Exenatide and Liraglutide) are approved and on the
market as adjunctive antidiabetic treatments. It is only a
matter of time until a gene therapy approach appropriate
for the clinic will develop and catch up to the small
molecule industry of agonists, antagonists, and inhibitors.
Theﬁrstandmostimportantbarriertocrossinthetransition
from the laboratory to the clinic is demonstration of the
safety of this approach. The use of the SG as a bioreactor
represents one such tissue that would allow this question to
be addressed with fewer complications, both physiologically
and regulatory, compared to other potential gene therapy
target tissues. It is apparent from the many successful
attempts using a gene therapy approach to express GLP-1
or exendin-4 in animal models, that success is dependent on
their sustained and, in the future, regulated expression.
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